Mabwell (688062.SH), a China-based biopharmaceutical company, announced on Thursday that it has dosed its first subject in a phase Ib/II trial of its novel Nectin-4 targeting ADC (R&D code: 9MW2821) in combination with PD-1 inhibitor intended for the treatment of locally advanced or metastatic urothelial carcinoma.

The clinical trial (CTR20232677) is intended to assess the safety, tolerability, preliminary efficacy, and pharmacokinetic profile of the product in combination with PD-1 inhibitor in subjects with locally advanced or metastatic urothelial carcinoma.

The product is a novel Nectin-4 aimed at ADC developed by the company's ADC development platform and automated high-throughput antibody discovery platform. It achieves site-specific modification of antibody via proprietary conjugate technology linkers and optimised ADC conjugation process and can specifically bind to Nectin-4 on the cell membrane surface, be internalised and release cytotoxic drug, and induce the apoptosis of tumour cells.